Fusen Pharmaceutical Company Limited (HKG:1652)
Hong Kong · Delayed Price · Currency is HKD 0.3350
0.00 (0.00%)
Jul 24, 2025, 3:52 PM HKT
HKG:1652 Revenue
In the year 2024, Fusen Pharmaceutical Company had annual revenue of 326.03M CNY, down -42.36%. Fusen Pharmaceutical Company had revenue of 129.71M in the half year ending December 31, 2024, a decrease of -60.23%.
Revenue
326.03M CNY
Revenue Growth
-42.36%
P/S Ratio
0.71
Revenue / Employee
288.27K CNY
Employees
1,131
Market Cap
247.67M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 326.03M | -239.58M | -42.36% |
| Dec 31, 2023 | 565.61M | 73.85M | 15.02% |
| Dec 31, 2022 | 491.76M | 106.09M | 27.51% |
| Dec 31, 2021 | 385.66M | -101.19M | -20.78% |
| Dec 31, 2020 | 486.85M | 79.47M | 19.51% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| Innovent Biologics | 10.03B |
| Akeso | 2.26B |
| WuXi Biologics | 19.87B |
| Sino Biopharmaceutical | 30.72B |
| CSPC Pharmaceutical Group | 28.99B |